Recent Q1 earnings calls from throughout the biopharmaceutical landscape have trended toward tariff talks and manufacturing reshoring. Companies continue to assuage investor concerns by both promoting their existing US manufacturing footprint, and by actively working to expand it.
Another handful of companies discussed their efforts to prioritize US manufacturing, seeking to mitigate revenue losses from tariffs and aid the US economy in the long term by utilizing domestic workers and supplies.
Emma Walmsley, CEO of British firm GSK, also highlighted her company’s robust US-manufacturing footprint. “We’re very pleased to break ground on our new state-of-the-art manufacturing facility in Marietta, Pennsylvania, this quarter,” she said. “This is squarely targeted on increasing manufacturing capacity for new pipeline products in the US and means that GSK will have six manufacturing sites in America.”
Read the article.